<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>LA062690-0105</title>
	</head>
	<body>
		<main>
			<p><P> June 26, 1990, Tuesday, Valley Edition  </P> <P> REGIONAL ROUNDUP: BAXTER HEALTHCARE TO SELL NEW BLOOD-CLOTTING DRUG  </P> <P> Baxter Healthcare Corp.'s Glendale-based Hyland division said it will begin  U.S. distribution of a drug made by Kabi Vitrum AB, a Swedish pharmaceutical  company, for patients with antithrombin III deficiency, a hereditary disorder  that impairs proper blood clotting.  </P> <P> The drug, ATnativ, received approval from the U.S. Food and Drug Administration  last December for marketing as an orphan drug, the term used for treatments for  diseases with a patient population of 200,000 or less. ATnativ has been  available in several European countries for clinical trials since the  mid-1970s.  </P> <P> Baxter Healthcare is a unit of Baxter International, a major health-care  products and services concern based in Deerfield, Ill.  </P></p>
		</main>
</body></html>
            